Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Pernelle NoizeAngela GrelaudJacques-Olivier BayChristine ChevreauMarine Gross-GoupilStéphane CulineJean-Marie FerrièreFlore MoulinPhilip RobinsonAurelie BalestraStéphanie LamarqueMarie-Agnès BernardRégis LassalleMagali RouyerCécile Droz-PerroteauNicholas MooreAnnie Fourrier-RéglatAlain RavaudPublished in: Pharmacoepidemiology and drug safety (2017)
Results from this large observational study suggest that effectiveness of sunitinib in first-line mRCC as predicted by clinical trials is maintained in real-life clinical practice. The expected benefit in poor-prognosis patients that were not evaluated in the pivotal clinical trial remains; however, questionable and long-term safety monitoring is still warranted. Copyright © 2017 John Wiley & Sons, Ltd.
Keyphrases
- metastatic renal cell carcinoma
- clinical trial
- poor prognosis
- end stage renal disease
- long non coding rna
- randomized controlled trial
- clinical practice
- systematic review
- chronic kidney disease
- newly diagnosed
- ejection fraction
- renal cell carcinoma
- phase ii
- prognostic factors
- study protocol
- open label
- phase iii
- stem cells
- mesenchymal stem cells